Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature

Gynecol Endocrinol. 2012 Jul;28(7):545-8. doi: 10.3109/09513590.2011.650745. Epub 2012 Mar 23.

Abstract

Objective: To report the outcomes from two cases of ovarian stimulation following the sole administration of gonadotrophin-releasing hormone agonist (GnRHa) in the context of in vitro fertilization (IVF).

Design: A case study was conducted.

Setting: National Referral Unit of Reproductive Medicine.

Patients: Two infertile women undergoing IVF participated in the study.

Interventions: Controlled ovarian hyperstimulation using a long protocol. GnRHa (Buserelin) was started in the luteal phase, in a dose of 600 µg/day, for 12 days.

Main outcome measures: Number of retrieved oocytes, fertilization rate, number of embryos transferred, implantation rate, ongoing pregnancy, and live birth.

Results: Both women underwent egg retrieval and transfer of good quality embryos. One of them conceived and recently gave birth to a healthy full-term baby.

Conclusions: The ovarian hyperstimulation after the sole administration of GnRHa is a rare condition. Oocyte retrieval may be a reasonable treatment under these circumstances instead of cycle cancellation. As far as it is known, this is the third case reported of a live birth following the sole administration of GnRHa in the context of IVF.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Buserelin / administration & dosage
  • Buserelin / adverse effects*
  • Embryo Transfer
  • Female
  • Fertility Agents, Female / administration & dosage
  • Fertility Agents, Female / adverse effects*
  • Fertilization in Vitro*
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Infertility, Female / therapy*
  • Ovarian Hyperstimulation Syndrome / prevention & control
  • Ovulation Induction / adverse effects*
  • Pregnancy
  • Term Birth
  • Treatment Failure

Substances

  • Fertility Agents, Female
  • Gonadotropin-Releasing Hormone
  • Buserelin